

Dupuytren Disease Market Forecasts to 2034 – Global Analysis By Disease Type (Type I, Type II and Type III), Treatment (Needle Aponeurotomy, Surgery, Enzyme Injection, Radiation Therapy, Steroid Shot, Occupational Therapy and Other Treatments), Diagnosis, Route of Administration, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/D178F9F9E991EN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: D178F9F9E991EN

Abstracts

According to Statistics MRC, the Global Dupuytren Disease Market is accounted for \$5.3 billion in 2026 and is expected to reach \$8.9 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Dupuytren's disease, also known as Dupuytren's contracture, is a medical condition that affects the hands and fingers. It is characterized by the thickening and tightening of the connective tissue beneath the skin in the palm of the hand. The primary feature of Dupuytren's disease is the development of nodules or lumps in the palm, which may progress to form cords of tissue that pull the affected fingers inward.

Market Dynamics:

Driver:

Increasing incidence

As the global population ages, particularly in regions with a higher prevalence of this condition, there is a natural rise in the number of individuals affected by Dupuytren's disease. Moreover, heightened awareness and improved diagnostic capabilities contribute to the more accurate and timely identification of Dupuytren's disease cases.

Overall, the escalating incidence of Dupuytren's disease propels market growth by creating opportunities for improved patient care and the development of novel treatment modalities.

Restraint:

High cost of treatment

The cost of treatment serves as a notable restraint in the Dupuytren's disease market, impacting the demand. Surgical interventions, such as fasciectomy or fasciotomy, and certain pharmaceutical treatments involve substantial costs; include hospitalization, surgeon fees, and post-operative care. Moreover, the potential for recurrence in Dupuytren's disease necessitates additional treatments, amplifying the overall cost for patients over time.

Opportunity:

Technological innovations in treatment options

Technological innovations in treatment options are a significant driver in the Dupuytren disease market, accelerating the demand. The introduction of collagenase injections has revolutionized the treatment of Dupuytren disease. Collagenase is an enzyme that can break down the contracted tissue, enabling the straightening of the affected fingers. This non-surgical approach avoids the need for incisions or anaesthesia and provides patients with a less-invasive treatment option.

Threat:

Limited treatment options

Dupuytren disease exhibits significant heterogeneity among patients, with variations in disease severity, affected hand joints, and response to treatments. This variability makes it challenging to predict treatment outcomes and select the most appropriate intervention for each individual. Some patients may experience limited improvement or recurrence of contractures even after undergoing treatment, leading to the need for additional interventions or a combination of treatment approaches. Therefore, the limited treatment options in the Dupuytren disease market pose a challenge to market growth.

Covid-19 Impact

The COVID-19 pandemic has significantly impacted the Dupuytren disease market, introducing challenges that have influenced both patient care and market dynamics. The healthcare system's prioritization of resources toward managing the pandemic has led to disruptions in routine medical services, delaying the diagnosis and treatment of Dupuytren disease. Additionally, supply chain disruptions and manufacturing challenges during the pandemic have affected the availability and distribution of Dupuytren-specific treatments.

The radiation therapy segment is expected to be the largest during the forecast period

The radiation therapy segment is estimated to hold the largest share. Radiation therapy involves the use of high-energy radiation to target and reduce abnormal tissue growth associated with Dupuytren's disease. This non-invasive treatment modality is particularly considered for individuals with advanced stages of the disease, characterized by contractures and nodules impacting hand function. It is especially beneficial in cases where multiple fingers are affected or when the disease recurs after surgery.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have lucrative growth during the forecast period. In Dupuytren's disease the parenteral route of administration plays a pivotal role in delivering therapeutic interventions directly into the patient's system, bypassing the gastrointestinal tract. This direct approach ensures rapid absorption and distribution of the therapeutic agent, allowing for optimal efficacy in managing the disease's symptoms. Moreover, the parenteral route minimizes the risk of degradation or alteration of the drug in the gastrointestinal environment, enhancing its bioavailability.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The region comprises advanced healthcare infrastructure, a well-established regulatory framework, and a high prevalence of Dupuytren's disease, particularly in the aging population. The region's healthcare landscape encourages the adoption of advanced surgical procedures, injectable treatments, and non-invasive options. Moreover, collaborations between research institutions, pharmaceutical companies, and

healthcare providers contribute to the development of novel therapies in this region.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. In this region, there is a notable shift toward embracing advanced medical technologies and therapies for Dupuytren's disease. Increased research initiatives, collaborations between regional and international healthcare entities, and evolving healthcare policies contribute to the development and adoption of innovative treatment options. The market's growth in this region is further propelled by economic development, improved healthcare affordability, and a heightened focus on patient-centric care.

Key players in the market

Some of the key players in the Dupuytren Disease Market include Pfizer Inc, AstraZeneca, Endo International plc, LEO Pharma A/S, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Meyers Squibb Company, Fresenius Kabi AG, GSK plc, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd, Novartis AG, Bayer AG., Johnson & Johnson Services Ltd. and Aurobindo Pharma.

Key Developments:

In August 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

Disease Types Covered:

Type I

Type II

Type III

Treatments Covered:

Needle Aponeurotomy

Surgery

Enzyme Injection

Radiation Therapy

Steroid Shot

Occupational Therapy

Other Treatments

Diagnosis Covered:

X-Ray

Physical Examination

Other Diagnosis

Route of Administrations Covered:

Parenteral

Oral

Other Route of Administrations

Distribution Channels Covered:

Online Pharmacy

Retail Pharmacy

Other Distribution Channels

End Users Covered:

Clinics

Hospitals

Academic & Research Institutes

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL DUPUYTREN DISEASE MARKET, BY DISEASE TYPE

Dupuytren Disease Market Forecasts to 2034 – Global Analysis By Disease Type (Type I, Type II and Type III), T...

- 5.1 Introduction
- 5.2 Type I
- 5.3 Type II
- 5.4 Type III

6 GLOBAL DUPUYTREN DISEASE MARKET, BY TREATMENT

- 6.1 Introduction
- 6.2 Needle Aponeurotomy
- 6.3 Surgery
- 6.4 Enzyme Injection
- 6.5 Radiation Therapy
- 6.6 Steroid Shot
- 6.7 Occupational Therapy
- 6.8 Other Treatments

7 GLOBAL DUPUYTREN DISEASE MARKET, BY DIAGNOSIS

- 7.1 Introduction
- 7.2 X-Ray
- 7.3 Physical Examination
- 7.4 Other Diagnosis

8 GLOBAL DUPUYTREN DISEASE MARKET, BY ROUTE OF ADMINISTRATION

- 8.1 Introduction
- 8.2 Parenteral
- 8.3 Oral
- 8.4 Other Route Of Administrations

9 GLOBAL DUPUYTREN DISEASE MARKET, BY DISTRIBUTION CHANNEL

- 9.1 Introduction
- 9.2 Online Pharmacy
- 9.3 Retail Pharmacy
- 9.4 Other Distribution Channels

10 GLOBAL DUPUYTREN DISEASE MARKET, BY END USER

- 10.1 Introduction
- 10.2 Clinics
- 10.3 Hospitals
- 10.4 Academic & Research Institutes

11 GLOBAL DUPUYTREN DISEASE MARKET, BY GEOGRAPHY

- 11.1 Introduction
- 11.2 North America
 - 11.2.1 US
 - 11.2.2 Canada
 - 11.2.3 Mexico
- 11.3 Europe
 - 11.3.1 Germany
 - 11.3.2 UK
 - 11.3.3 Italy
 - 11.3.4 France
 - 11.3.5 Spain
 - 11.3.6 Rest of Europe
- 11.4 Asia Pacific
 - 11.4.1 Japan
 - 11.4.2 China
 - 11.4.3 India
 - 11.4.4 Australia
 - 11.4.5 New Zealand
 - 11.4.6 South Korea
 - 11.4.7 Rest of Asia Pacific
- 11.5 South America
 - 11.5.1 Argentina
 - 11.5.2 Brazil
 - 11.5.3 Chile
 - 11.5.4 Rest of South America
- 11.6 Middle East & Africa
 - 11.6.1 Saudi Arabia
 - 11.6.2 UAE
 - 11.6.3 Qatar
 - 11.6.4 South Africa
 - 11.6.5 Rest of Middle East & Africa

12 KEY DEVELOPMENTS

- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies

13 COMPANY PROFILING

- 13.1 Pfizer Inc
- 13.2 AstraZeneca
- 13.3 Endo International plc
- 13.4 LEO Pharma A/S
- 13.5 Spear Pharmaceuticals
- 13.6 Hikma Pharmaceuticals PLC
- 13.7 Bristol-Meyers Squibb Company
- 13.8 Fresenius Kabi AG
- 13.9 GSK plc
- 13.10 Actiza Pharmaceutical Private Limited
- 13.11 Nantong Jinghua Pharmaceutical Co., Ltd
- 13.12 Novartis AG
- 13.13 Bayer AG.
- 13.14 Johnson & Johnson Services Ltd.
- 13.15 Aurobindo Pharma

List Of Tables

LIST OF TABLES

Table 1 Global Dupuytren Disease Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Dupuytren Disease Market Outlook, By Disease Type (2023–2034) (\$MN)

Table 3 Global Dupuytren Disease Market Outlook, By Type I (2023–2034) (\$MN)

Table 4 Global Dupuytren Disease Market Outlook, By Type II (2023–2034) (\$MN)

Table 5 Global Dupuytren Disease Market Outlook, By Type III (2023–2034) (\$MN)

Table 6 Global Dupuytren Disease Market Outlook, By Treatment (2023–2034) (\$MN)

Table 7 Global Dupuytren Disease Market Outlook, By Needle Aponeurotomy (2023–2034) (\$MN)

Table 8 Global Dupuytren Disease Market Outlook, By Surgery (2023–2034) (\$MN)

Table 9 Global Dupuytren Disease Market Outlook, By Enzyme Injection (2023–2034) (\$MN)

Table 10 Global Dupuytren Disease Market Outlook, By Radiation Therapy (2023–2034) (\$MN)

Table 11 Global Dupuytren Disease Market Outlook, By Steroid Shot (2023–2034) (\$MN)

Table 12 Global Dupuytren Disease Market Outlook, By Occupational Therapy (2023–2034) (\$MN)

Table 13 Global Dupuytren Disease Market Outlook, By Other Treatments (2023–2034) (\$MN)

Table 14 Global Dupuytren Disease Market Outlook, By Diagnosis (2023–2034) (\$MN)

Table 15 Global Dupuytren Disease Market Outlook, By X-Ray (2023–2034) (\$MN)

Table 16 Global Dupuytren Disease Market Outlook, By Physical Examination (2023–2034) (\$MN)

Table 17 Global Dupuytren Disease Market Outlook, By Other Diagnosis (2023–2034) (\$MN)

Table 18 Global Dupuytren Disease Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 19 Global Dupuytren Disease Market Outlook, By Parenteral (2023–2034) (\$MN)

Table 20 Global Dupuytren Disease Market Outlook, By Oral (2023–2034) (\$MN)

Table 21 Global Dupuytren Disease Market Outlook, By Other Route Of Administrations (2023–2034) (\$MN)

Table 22 Global Dupuytren Disease Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 23 Global Dupuytren Disease Market Outlook, By Online Pharmacy (2023–2034)

(\$MN)

Table 24 Global Dupuytren Disease Market Outlook, By Retail Pharmacy (2023–2034)

(\$MN)

Table 25 Global Dupuytren Disease Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 26 Global Dupuytren Disease Market Outlook, By End User (2023–2034) (\$MN)

Table 27 Global Dupuytren Disease Market Outlook, By Clinics (2023–2034) (\$MN)

Table 28 Global Dupuytren Disease Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 29 Global Dupuytren Disease Market Outlook, By Academic & Research Institutes (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Dupuytren Disease Market Forecasts to 2034 – Global Analysis By Disease Type (Type I, Type II and Type III), Treatment (Needle Aponeurotomy, Surgery, Enzyme Injection, Radiation Therapy, Steroid Shot, Occupational Therapy and Other Treatments), Diagnosis, Route of Administration, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/D178F9F9E991EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D178F9F9E991EN.html>